Abstracts tagged "Effective"

Abstract Number: 1302 • 2019 ACR/ARP Annual Meeting
Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
Marc C. Hochberg¹, John Carrino ², Thomas Schnitzer ³, Ali Guermazi ⁴, Eric Vignon ⁵, David Walsh ⁶, Alexander White ⁷, Satoru Nakajo ⁸, Robert Fountaine ⁹, Anne Hickman ⁹, Glenn Pixton ¹⁰, Lars Viktrup ¹¹, Mark T. Brown ⁹, Christine R. West ⁹ and Kenneth M. Verburg ⁹, ¹University of Maryland School of Medicine, Baltimore, MD, ²Hospital for Special Surgery, New York, NY, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Boston Medical Center, Boston, ⁵Université Claude Bernard Lyon 1, Lyon, France, ⁶Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom, ⁷Progressive Medical Research, Port Orange, FL, ⁸Nakajo Orthopaedic Clinic, Miyagi, Japan, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, Morrisville, NC, ¹¹Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tanezumab is a monoclonal antibody that inhibits nerve growth factor and is under investigation for chronic pain treatment. Tanezumab administered intravenously was effective and…
Abstract Number: 1657 • 2018 ACR/ARHP Annual Meeting
The Effect of Guselkumab on Enthesitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis
Philip Helliwell¹, Alice B Gottlieb², Atul A. Deodhar³, Wolf-Henning Boehncke⁴, Dennis McGonagle¹, Xie L. Xu⁵, Stephen Xu⁵, Yuhua Wang⁵, Elizabeth C Hsia^5,6, Chetan S Karyekar⁵ and Philip J. Mease⁷, ¹U of Leeds, Leeds, United Kingdom, ²NY Medical College, Metropolitan Hospital, NY, NY, ³Oregon Health & Science U, Portland, OR, ⁴U of Geneva, Geneva, Switzerland, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶U Penn School of Medicine, Phila, PA, ⁷Swedish Medical Center & U of Wash, Seattle, WA
Background/Purpose: In a Phase 2 study, Guselkumab (GUS) was shown to be safe & effective in pts w/active PsA w/meaningful improvements in enthesitis. To evaluate…
Abstract Number: 1756 • 2018 ACR/ARHP Annual Meeting
Systematic Review of the Clinical Effectiveness of Treatments in Eosinophilic Granulomatosis with Polyangiitis
Scott Doyle¹, Annete Njue², Matthew Lyall², Rebecca Rushton², Anne Heyes² and Maebh Kelly³, ¹Value Evidence and Outcomes, GlaxoSmithKline, London, United Kingdom, ²RTI Health Solutions, Manchester, United Kingdom, ³Pope Woodhead, London, United Kingdom
Background/Purpose: To better understand the available clinical effectiveness data in eosinophilic granulomatosis with polyangiitis (EGPA), a systematic literature review was undertaken. The primary objective of…
Abstract Number: 1786 • 2018 ACR/ARHP Annual Meeting
Favourable Response to Rituximab for the Treatment of IgG4-Related Disease: Long-Term Follow-up of 10 Patients Resistant to Glucocorticoids and Immunosuppressives
Emin Oguz¹, Gizem Dagcı², Murat Erdugan¹, Bahar Artim-Esen¹, Ahmet Gül¹, Lale Ocal¹ and Murat Inanc³, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Istanbul Unıversity, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey
Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is a systemic, immuno-mediated fibro-inflammatory disease that affects various organ systems, with typical pathological findings and increased IgG4 levels. Glucocorticoids…
Abstract Number: 2187 • 2018 ACR/ARHP Annual Meeting
Specialist Link Telephone Advice Cost Effectively Enhances Rheumatology Patient Care in Alberta, Canada
Yolanda Martens-Vanhilst¹, Dianne P. Mosher², Linda Slocombe¹ and Paul MacMullan³, ¹University of Calgary, Calgary, AB, Canada, ²Med, University of Calgary, Calgary, AB, Canada, ³Medicine, Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: The Calgary zone of Alberta Health Services serves a population of almost 2million Canadians over a wide geographical area and is underserved in terms…
Abstract Number: 2513 • 2018 ACR/ARHP Annual Meeting
Change in Disease Activity after Switching Etanercept (originator) to Biosimilar (Benepali) Is Associated with Active Disease at Baseline
Kaushik Rajamani¹ and Ernest Choy^2,3,4,5,6,7, ¹Adult Rheumatology, University Hospital of Wales, Cardiff, United Kingdom, ²Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ³Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom, ⁵CREATE Center, Cardiff University School of Medicine, Cardiff, Great Britain, ⁶Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ⁷CREATE Center, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Biosimilar contains a version of active substance similar of an already approved biological agent in terms of quality, characteristic, biological activity, safety and efficacy.…
Abstract Number: 2624 • 2018 ACR/ARHP Annual Meeting
Cost-Effectiveness of Swapping Strategy for Established Psoriatic Arthritis and Immediate Versus Standard Swapping Strategy for Early Psoriatic Arthritis
Dongze Wu¹, Tingting Xu², Isaac T. Cheng¹, Steven H.M. Lam¹, Jiang Yue¹, Priscilla Wong¹, Edmund Li¹, Tena K. Li¹ and Lai-Shan Tam³, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²China Center for Health Development Studies, Peking University, Beijing, China; Department of Health Policy and Administration, Peking University School of Public Health, Beijing, China, Beijing, China, ³Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong
Background/Purpose: For patients with psoriatic arthritis (PsA) failing the first TNF-inhibitor, switching to biologic DMARDs [bDMARDs] with different mechanism of actions (swapping strategy) may be…
Abstract Number: 2650 • 2018 ACR/ARHP Annual Meeting
Efficacy, Safety, and Predictor of Response to Belimumab in a Large Nationwide Cohort Study of Patients with Active Systemic Lupus Erythematosus
Luca Iaccarino¹, Francesca Saccon¹, Alessandro Mathieu², Matteo Piga³, Angela Ceribelli⁴, Carlo Selmi⁵, Paolo Cardinaletti⁶, Armando Gabrielli⁷, Andrea Di Matteo⁸, Rossella De Angelis⁹, Paola Faggioli¹⁰, Antonella Laria¹¹, Micaela Fredi¹², Francesca Regola¹³, Angela Tincani¹², Laura Andreoli¹⁴, Giulia Pazzola¹⁵, Carlo Salvarani¹⁵, Francesco Puppo¹⁶, Ottavia Magnani¹⁶, Marcella Prete¹⁷, Elisa Gremese¹⁸, Maria Gerosa¹⁹, Tania Ubiali²⁰, Enrica Bozzolo²¹, Valentina Canti²¹, Vito Racanelli¹⁷, Fabrizio Conti²², Fulvia Ceccarelli²³, Elena Bartoloni²⁴, Roberto Gerli²⁵, Antonio Lobasso²⁶, Amato de Paulis²⁷, Ginevra De Marchi²⁸, Salvatore De Vita²⁹, Alessandra Bortoluzzi³⁰, Marcello Govoni³⁰, Francesco Benvenuti³¹, Margherita Zen³², Marta Mosca³³, Chiara Tani³⁴, Maurizio Rossini³⁵, Giovanni Orsolini³⁵, Salvatore Scarpato³⁶, Ernico Brunetta³⁷, Aurora Zumbo³⁸, Giacomo Tanti³⁹ and Andrea Doria⁴⁰, ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²University of Cagliari, Cagliari, Italy, ³Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ⁴Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, ⁵Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ⁶University of Ancona, Ancona, Italy, ⁷Univeristy of Ancona, Ancona, Italy, ⁸Polytechnic University of Marche, Rheumatology Clinic, Jesi, Italy, ⁹Polytechnic University of Marche, Rheumatology Clinic, jesi, Italy, ¹⁰Hospital of Legnano, Legnano, Italy, ¹¹Hospital of Magenta, Magenta, Italy, ¹²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹³University of Brescia, Brescia, Italy, ¹⁴Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ¹⁵University of Reggio Emilia, Reggio Emilia, Italy, ¹⁶University of Genova, Genova, Italy, ¹⁷University of Bari, Bari, Italy, ¹⁸Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ¹⁹Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ²⁰Istituto Gaetano Pini, University of Milano, Milano, Italy, ²¹Hospital San Raffaele, Milano, Italy, ²²Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ²³UO Complessa Reumatologia, Policlinico Umberto I Università Sapienza di Roma, Rome, Italy, ²⁴Rheumatology Unit, University of Perugia, Perugia, Italy, ²⁵Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ²⁶University Federico II of Napoli, Napoli, Italy, ²⁷Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy, ²⁸Hospital/University of Udine, Udine, Italy, ²⁹Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ³⁰UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ³¹University of Padova, Padova, Italy, ³²Division of Rheumatology, University of Padova, Padova, Italy, ³³Rheumatology Unit, University of Pisa, Pisa, Italy, ³⁴Univeristy of Pisa, Pisa, Italy, ³⁵Rheumatology Unit, University of Verona, Verona, Italy, ³⁶Hospital of Salerno, Salerno, Italy, ³⁷Humanitas Hospital, Milano, Italy, ³⁸Humnaitas Hospital, Milano, Italy, ³⁹Catholic University of the sacred hearth, Roma, Italy, ⁴⁰University and Azienda Ospedaliera of Padova, Padova, Italy
Background/Purpose: To investigate effectiveness, safety, and predictors of response to belimumab in patients with active SLE in clinical practice setting. Methods: Four hundred and one…
Abstract Number: 256 • 2018 ACR/ARHP Annual Meeting
The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences
Robert S. Katz, Rush University Medical Center, Chicago, IL
Background/Purpose: We asked patients with fibromyalgia to rank the effectiveness of medications they have tried. Methods: In a rheumatology office practice, 95 patients (mean age…
Abstract Number: 594 • 2018 ACR/ARHP Annual Meeting
Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE
Anne C. Bay-Jensen¹, Christian S. Thudium¹, Claus Christiansen² and Morten A. Karsdal¹, ¹Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Clinical Development, Herlev, Denmark
Background/Purpose: Tocilizumab, anti-interleukin 6 receptor (IL-6R) therapy, is an effective treatment of rheumatoid arthritis (RA). However, a significant amount of patients do not respond adequately…
Abstract Number: 633 • 2018 ACR/ARHP Annual Meeting
The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis
Dafna D Gladman¹, Wolf-Henning Boehncke², Alice B Gottlieb³, Philip Helliwell⁴, Peter Nash⁵, Xie L. Xu⁶, Stephen Xu⁶, Yuhua Wang⁶, Elizabeth C Hsia^6,7, Chetan S Karyekar⁶ and Atul A. Deodhar⁸, ¹Krembil Research Institute, U of Toronto, Toronto, ON, Canada, ²U of Geneva, Geneva, Switzerland, ³NY Medical College, Metropolitan Hospital, NY, NY, ⁴U of Leeds, Leeds, United Kingdom, ⁵U of Queensland, Brisbane, Australia, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷U Penn School of Medicine, Phila, PA, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: In a Ph2 study, GUS was shown to be safe&effective in pts w/active PsA. We evaluated effect of GUS on dactylitis in subset of…
Abstract Number: 1261 • 2018 ACR/ARHP Annual Meeting
Development a Core Domain Set to Assess Shared Decision Making Interventions in Rheumatology: An OMERACT White Paper to Facilitate Endorsement
Karine Toupin-April¹, Jennifer Barton^2,3, Liana Fraenkel⁴, Alexa Meara⁵, Linda Li⁶, Peter Brooks⁷, Maarten de Wit⁸, Dawn Stacey^9,10, France Légaré¹¹, Beverly Shea^9,12,13, Anne Lyddiatt¹⁴, Catherine Hofstetter¹⁵, Robin Christensen¹⁶, Marieke Scholte-Voshaar^17,18, Maria Suarez-Almazor¹⁹, Annelies Boonen²⁰, Tanya Meade^21,22, Lyn March²², Janet Elizabeth Jull⁹, Willemina Campbell²³, Rieke Alten²⁴, Suvi Karuranga²⁵, Esi Morgan²⁶, Jessica Kaufmann²⁷, Sophie Hill²⁷, Lara J. Maxwell^9,10, Dorcas Beaton²⁸, Yasser El-Miedany²⁹, Shikha Mittoo³⁰, Susan J. Bartlett³¹, Jasvinder A. Singh³² and Peter Tugwell³³, ¹Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ²VA Portland Health Care System, Portland, OR, ³Oregon Health & Science University, Portland, OR, ⁴Yale University School of Medicine, New Haven, CT, ⁵Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Arthritis Research Canada, Richmond, BC, Canada, ⁷The University of Melbourne, Victoria, Australia, ⁸EULAR standing committee of PARE, Zurich, Switzerland, ⁹University of Ottawa, Ottawa, ON, Canada, ¹⁰The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ¹¹Université Laval, Montreal, QC, Canada, ¹²Bruyere Research Institute, Ottawa, ON, Canada, ¹³School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada, ¹⁴Musculoskeletal Group, Cochrane Collaboration, Hamilton, ON, Canada, ¹⁵OMERACT patient research partner group, Ottawa, ON, Canada, ¹⁶Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ¹⁷University of Twente, Enschede, ON, Netherlands, ¹⁸OMERACT patient research partner group, Enschede, Netherlands, ¹⁹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²⁰Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands, Maastricht, Netherlands, ²¹Western Sydney University, New South Wales, Australia, ²²University of Sydney, New South Wales, Australia, ²³OMERACT patient research partner group, Toronto, ON, Canada, ²⁴University Medicine Berlin, Berlin, Germany, ²⁵Access to Medicine Foundation, Haarlem, Netherlands, ²⁶University of Cincinnati, Cincinnati, OH, ²⁷La Trobe University, Victoria, Australia, ²⁸Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada, ²⁹Ain Shams University, Cairo, Egypt, ³⁰Involved medicine, Toronto, ON, Canada, ³¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³²Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³³Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada
Background/Purpose: Shared decision making (SDM) improves decisional outcomes and patient-physician communication and holds great potential for improving the management of various rheumatology conditions. However, the…
Abstract Number: 1546 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Corticosteroids in Rheumatoid Arthritis: Systematic Literature Review and Practical Recommendations
Raimon Sanmartí¹, Jesús Tornero Molina², Francisco Javier Narváez³, Alejandro Muñoz⁴, Elena Garmendia⁵, Ana M. Ortiz Garcia⁶, Miguel A. Abad⁷, Patricia Moya⁸, Maria Lourdes Mateo⁹, Delia Reina¹⁰, Juan Salvatierra Osorio¹¹, Sergio Rodriguez¹², Ana Rubial Escribano¹³, Natalia Palmou-Fontana¹⁴ and Jaime Calvo-Alén¹⁵, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Unit, Hospital de Guadalajara, Guadalajara, Spain, ³Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁵Rheumatology, Hospital Universitario Cruces. Barakaldo. Spain, Barakaldo, Spain, ⁶Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁷FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain, ⁸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁹Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁰Rheumatology, Hospital Moises Broggi, Sant Joan Despí, Spain, ¹¹Complejo Hospitalario Universitario de Granada, Granada, Spain, ¹²Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain, ¹³Rheumatology, Hospital Alfredo Espinosa, Urduliz, Spain, ¹⁴Hospital Universitario Marqués de Valdecilla, IDIVAL. Universidad of Cantabria, Santander, Spain, ¹⁵Rheumatology Department, Hospital Universitario Araba. Vitoria-Gasteiz, Alava, Spain
Background/Purpose: Corticosteroids are effective in rheumatoid arthritis (RA) patients but their adverse events limit their use. The aim of this study was to: 1) To…
Abstract Number: 1552 • 2018 ACR/ARHP Annual Meeting
No Effect of Concomitant Glucocorticoid Therapy on Efficacy and Safety of Tocilizumab Monotherapy Found in Rheumatoid Arthritis Clinical Trials
Mary Safy¹, Johannes W. G. Jacobs¹, Michael Edwardes², Maria JH de Hair¹, Xavier M Teitsma¹, Paco MJ Welsing¹, Michelle EA Borm³, Yves Luder⁴, Jacob van Laar¹, Attila Pethö-Schramm⁴ and Johannes W. J. Bijlsma⁵, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Everest Clinical Research, Markham, ON, Canada, ³Roche Nederland BV, Woerden, Netherlands, ⁴F. Hoffmann-La Roche, Basel, Switzerland, ⁵Rheumatology & Clinical Immunology department University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
No effect of concomitant glucocorticoid therapy on efficacy and safety of tocilizumab monotherapy in rheumatoid arthritis clinical trialsM. Safy1, J.W.G. Jacobs1, M. Edwardes2, M.J.H. de…
Abstract Number: 449 • 2017 ACR/ARHP Annual Meeting
Medical Bugs for Pain Relief in Patients with Rheumatoid Arthritis, a Systematic Review
Rongqiang Zhang¹, Puwei Yuan², Jia Li³, Bo Dong¹, Wulin Kang³, Stephanie Hyon⁴, Raveendhara R. Bannuru⁵, William F. Harvey⁴ and Chenchen Wang⁴, ¹Shaanxi University of Chinese Medicine, Xianyang 712046, China, Xianyang, China, ²Shaanxi University of Chinese Medicine, Xianyang 712046, China, XianYang, China, ³Shaanxi University of Chinese Medicine, Xianyang, China, ⁴Rheumatology, Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA, ⁵Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA
Background/Purpose: Medical bugs, a term used to describe insects and arthropods for medical treatment, have been widely used in the past centuries for pain relief.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].